BGM
Get informed when a big investor buys or sells
+ FollowOvervalued by 120.2% based on the discounted cash flow analysis.
| Market cap | $124.65 Million |
|---|---|
| Enterprise Value | $119.91 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.18 |
| Beta | 1.81 |
| Outstanding Shares | 128,205,667 |
| P/E Ratio | -2 |
|---|---|
| PEG | 0.03 |
| Price to Sales | - |
| Price to Book Ratio | 0.09 |
| Enterprise Value to Revenue | 1.77 |
| Enterprise Value to EBIT | -6.32 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.01 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.16%▼ 0.58% |
|---|---|
| Total Invested | $63,385▼ 92.69% |
| Investors Holding | 14▲ 6.00% |
No data
Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycl...